{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T18:00:12Z","timestamp":1791568812641,"version":"4.3.4"},"reference-count":15,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T00:00:00Z","timestamp":1743638400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Gilead Sciences, Inc"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The combination of 2 broadly neutralizing antibodies (bNAbs), teropavimab and zinlirvimab, plus the capsid inhibitor lenacapavir, is a potential twice-yearly regimen for HIV-1 treatment. The level of bNAb susceptibility to maintain virologic suppression is unknown; therefore, we evaluated this combination in participants meeting stringent viral sensitivity criteria to only 1 of the 2 bNAbs.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This was a pilot study within a proof-of-concept phase 1b study.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>No serious treatment-emergent adverse events occurred and 8 of 10 participants remained virologically suppressed at week 26.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>More inclusive bNAb susceptibility criteria may be appropriate for future studies of this combination treatment.<\/jats:p>\n                  <jats:p>Clinical Trials Registration. NCT04811040.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/infdis\/jiaf159","type":"journal-article","created":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T16:24:47Z","timestamp":1743351887000},"page":"1440-1444","source":"Crossref","is-referenced-by-count":12,"title":["Lenacapavir Plus 2 Broadly Neutralizing Antibodies, Teropavimab and Zinlirvimab, for People With HIV-1 Highly Susceptible to Either Teropavimab or Zinlirvimab"],"prefix":"10.1093","volume":"231","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4938-0644","authenticated-orcid":false,"given":"Joseph J","family":"Eron","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, University of North Carolina , Chapel Hill, North Carolina ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul P","family":"Cook","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, East Carolina University , Greenville, North Carolina ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1748-8690","authenticated-orcid":false,"given":"Megha L","family":"Mehrotra","sequence":"additional","affiliation":[{"name":"Cinical Research, Gilead Sciences, Inc , Foster City, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hailin","family":"Huang","sequence":"additional","affiliation":[{"name":"Biostatistics, Gilead Sciences, Inc , Foster City, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1727-8693","authenticated-orcid":false,"given":"Marina","family":"Caskey","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular Immunology, Rockefeller University , New York, New York ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordon E","family":"Crofoot","sequence":"additional","affiliation":[{"name":"Crofoot MD Clinic and Research Center , Houston, Texas ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Gorgos","sequence":"additional","affiliation":[{"name":"AXCES Research Group , Santa Fe, New Mexico ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurie A","family":"VanderVeen","sequence":"additional","affiliation":[{"name":"Clinical Virology, Gilead Sciences, Inc , Foster City, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3076-0003","authenticated-orcid":false,"given":"Yanan","family":"Zheng","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology, Gilead Sciences, Inc , Foster City, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean E","family":"Collins","sequence":"additional","affiliation":[{"name":"Clinical Development, Gilead Sciences, Inc , Foster City, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olayemi O","family":"Osiyemi","sequence":"additional","affiliation":[{"name":"Triple O Research Institute PA , West Palm Beach, Florida ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Brinson","sequence":"additional","affiliation":[{"name":"Central Texas Clinical Research , Austin, Texas ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edwin","family":"DeJesus","sequence":"additional","affiliation":[{"name":"Orlando Immunology Center , Orlando, Florida ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,4,3]]},"reference":[{"key":"2025071111131131300_jiaf159-B1","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1177\/09564624231169329","article-title":"Barriers to adherence to antiretroviral therapy: identifying priority areas for people with HIV and healthcare professionals","volume":"34","author":"Mate","year":"2023","journal-title":"Int J STD AIDS"},{"key":"2025071111131131300_jiaf159-B2","doi-asserted-by":"crossref","first-page":"e332","DOI":"10.1016\/S2352-3018(23)00051-6","article-title":"Long-acting antiretrovirals and HIV treatment adherence","volume":"10","author":"Nachega","year":"2023","journal-title":"Lancet HIV"},{"key":"2025071111131131300_jiaf159-B3","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1016\/S2352-3018(22)00291-0","article-title":"Lenacapavir administered every 26 weeks or daily in combination with oral daily antiretroviral therapy for initial treatment of HIV: a randomised, open-label, active-controlled, phase 2 trial","volume":"10","author":"Gupta","year":"2023","journal-title":"Lancet HIV"},{"key":"2025071111131131300_jiaf159-B4","author":"Gilead Sciences, Inc","year":"2022"},{"key":"2025071111131131300_jiaf159-B5","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/s41591-018-0001-2","article-title":"A single injection of crystallizable fragment domain-modified antibodies elicits durable protection from SHIV infection","volume":"24","author":"Gautam","year":"2018","journal-title":"Nat Med"},{"key":"2025071111131131300_jiaf159-B6","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1097\/QAI.0000000000003528","article-title":"Susceptibility screening of HIV-1 viruses to broadly neutralizing antibodies, teropavimab and zinlirvimab, in people with HIV-1 suppressed by antiretroviral therapy","volume":"98","author":"Selzer","year":"2025","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2025071111131131300_jiaf159-B7","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1038\/s41591-018-0186-4","article-title":"Safety and antiviral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals","volume":"24","author":"Bar-On","year":"2018","journal-title":"Nat Med"},{"key":"2025071111131131300_jiaf159-B8","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1038\/s41586-022-04597-1","article-title":"Prolonged viral suppression with anti-HIV-1 antibody therapy","volume":"606","author":"Gaebler","year":"2022","journal-title":"Nature"},{"key":"2025071111131131300_jiaf159-B9","doi-asserted-by":"crossref","first-page":"e146","DOI":"10.1016\/S2352-3018(23)00293-X","article-title":"Safety of teropavimab and zinlirvimab with lenacapavir once every 6 months for HIV treatment: a phase 1b, randomised, proof-of-concept study","volume":"11","author":"Eron","year":"2024","journal-title":"Lancet HIV"},{"key":"2025071111131131300_jiaf159-B10","author":"Tebas"},{"key":"2025071111131131300_jiaf159-B11","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1056\/NEJMoa1608243","article-title":"Effect of HIV antibody VRC01 on viral rebound after treatment interruption","volume":"375","author":"Bar","year":"2016","journal-title":"N Engl J Med"},{"key":"2025071111131131300_jiaf159-B12","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/nature14411","article-title":"Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117","volume":"522","author":"Caskey","year":"2015","journal-title":"Nature"},{"key":"2025071111131131300_jiaf159-B13","doi-asserted-by":"crossref","first-page":"3212","DOI":"10.1038\/s41591-023-02611-1","article-title":"Viral and host mediators of non-suppressible HIV-1 viremia","volume":"29","author":"Mohammadi","year":"2023","journal-title":"Nat Med"},{"key":"2025071111131131300_jiaf159-B14","doi-asserted-by":"crossref","first-page":"e2845","DOI":"10.1093\/cid\/ciaa1754","article-title":"A high percentage of people with human immunodeficiency virus (HIV) on antiretroviral therapy experience detectable low-level plasma HIV-1 RNA following coronavirus disease 2019 (COVID-19)","volume":"73","author":"Peluso","year":"2021","journal-title":"Clin Inf Dis"},{"key":"2025071111131131300_jiaf159-B15","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.virusres.2011.09.018","article-title":"Quasispecies as a matter of fact: viruses and beyond","volume":"162","author":"Ojosnegros","year":"2011","journal-title":"Virus Res"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiaf159\/62846635\/jiaf159.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/231\/6\/1440\/62846635\/jiaf159.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/231\/6\/1440\/62846635\/jiaf159.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T15:13:20Z","timestamp":1752246800000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/231\/6\/1440\/8104459"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,3]]},"references-count":15,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,4,3]]},"published-print":{"date-parts":[[2025,7,11]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiaf159","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,6,15]]},"published":{"date-parts":[[2025,4,3]]}}}